Information Provided By: 
Fly News Breaks for February 27, 2019
RHHBY, ONCE
Feb 27, 2019 | 07:45 EDT
Stifel analyst Stephen Willey downgraded Spark Therapeutics (ONCE) to Hold from Buy and raised his price target on the stock to $114.50 from $65 to reflect the company's agreement to be acquired by Roche (RHHBY). Willey, who thinks the all-cash offer represents a highly attractive outcome for Spark shareholders and that the company represents a solid strategic fit for Roche, does not expect to see a better competitive offer emerge and expects a timely closing.
News For ONCE;RHHBY From the Last 2 Days
RHHBY
Apr 24, 2024 | 06:33 EDT
RHHBY
Apr 24, 2024 | 06:30 EDT
